Double-negative T cells utilize a TNFα–JAK1–ICAM-1 cytotoxic axis against acute myeloid leukemia
Open Access
- 12 June 2024
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (12) , 3013-3026
Abstract
Allogeneic double-negative T cells (DNTs) are a rare T-cell subset that effectively target acute myeloid leukemia (AML) without inducing graft-versus-host disease in an allogeneic setting. A phase 1 clinical trial demonstrated the feasibility, safety, and potential efficacy of allogeneic DNT therapy among patients with relapsed AML. However, the molecular mechanisms of DNT-mediated cytotoxicity against AML remain elusive. Thus, we used a flow cytometry–based high throughput screening to compare the surface molecule expression profile on DNTs during their interaction with DNT-susceptible or -resistant AML cells and identified a tumor necrosis factor α (TNFα)-dependent cytotoxic pathway in DNT-AML interaction. TNFα secreted by DNTs, upon encountering susceptible AML targets, sensitized AML cells to DNT-mediated killing, including those otherwise resistant to DNTs. Mechanistically, TNFα upregulated ICAM-1 on AML cells through a noncanonical JAK1-dependent pathway. DNTs then engaged with AML cells more effectively through an ICAM-1 receptor, lymphocyte function–associated antigen 1, leading to enhanced killing. These results reveal a TNFα–JAK1–ICAM-1 axis in DNT-mediated cytotoxicity against AML to improve therapeutic efficacy.Keywords
This publication has 49 references indexed in Scilit:
- NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TransplantationTransplantation and Cellular Therapy, 2010
- TNF receptor 2 pathway: drug target for autoimmune diseasesNature Reviews Drug Discovery, 2010
- The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high‐risk myelodysplastic syndromesCancer, 2008
- Regulation of JAK–STAT signalling in the immune systemNature Reviews Immunology, 2003
- Tumor necrosis factor alpha (TNF-alpha) activates Jak1/Stat3-Stat5B signaling through TNFR-1 in human B cells.2002
- A minor E-selectin ligand, CD65, is critical for extravascular infiltration of acute myeloid leukemia cellsLeukemia Research, 2001
- The Usefulness of CD64, Other Monocyte-Associated Antigens, and CD45 Gating in the Subclassification of Acute Myeloid Leukemias with Monocytic DifferentiationAmerican Journal of Clinical Pathology, 1998
- Induction of Jak/STAT Signaling by Activation of the Type 1 TNF ReceptorThe Journal of Immunology, 1998
- A Southwest Oncology Group phase II trial of recombinant tumor necrosis factor in metastatic breast cancerCancer, 1991
- A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study.1990